Tang Qing-Xi, Wang Lu-Chuan, Wang Yu, Gao Hong-da, Hou Zhi-Ling
First Ward of Orthopedis Department.
First Ward of Orthopedis Department, Jiamusi Hospital of Traditional Chinese Medicine.
Medicine (Baltimore). 2019 Feb;98(6):e14442. doi: 10.1097/MD.0000000000014442.
This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MAP) for the treatment of patients with osteosarcoma.
We will retrieve the studies from the following 9 electronic databases: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, the Cumulative Index to Nursing and Allied Health Literature, the Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data. Two independent researchers will screen and select the relevant papers for eligibility after the search strategies have been conducted. All articles up to the present in any language, region will be considered in this study. A systematic review and data synthesis will be performed of randomized controlled trials of MAP for the treatment of patients with osteosarcoma. The primary outcome includes event-free survival. The secondary outcomes consist of overall survival, quality of life, and toxicity. In addition, 2 independent researchers will extract data, and will assess the quality of included studies by using Cochrane risk of bias tool. Results data will be pooled and meta-analysis will be conducted if >2 eligible studies will be included.
This systematic review will evaluate the efficacy and safety of MAP for the treatment of patients with osteosarcoma.
The findings of this study will summarize the up-to-date evidence of MAP for osteosarcoma, and may provide the guidance for the clinical practice, as well as the health policy maker.
PROSPERO CRD42018120004.
本系统评价将探讨甲氨蝶呤、阿霉素和顺铂（MAP）治疗骨肉瘤患者的疗效和安全性。
我们将从以下9个电子数据库检索研究：Cochrane对照试验中心注册库、EMBASE、MEDLINE、护理及相关健康文献累积索引、补充与替代医学数据库、中国生物医学文献数据库、中国知网、维普资讯和万方数据。两名独立研究人员将在执行检索策略后筛选并选择相关论文以确定其是否符合纳入标准。本研究将考虑所有语言、地区截至目前的所有文章。将对MAP治疗骨肉瘤患者的随机对照试验进行系统评价和数据综合分析。主要结局包括无事件生存期。次要结局包括总生存期、生活质量和毒性。此外，两名独立研究人员将提取数据，并使用Cochrane偏倚风险工具评估纳入研究的质量。如果纳入≥2项符合条件的研究，将汇总结果数据并进行荟萃分析。
本系统评价将评估MAP治疗骨肉瘤患者的疗效和安全性。
本研究结果将总结MAP治疗骨肉瘤的最新证据，并可能为临床实践以及卫生政策制定者提供指导。
PROSPERO注册号：PROSPERO CRD42018120004。
